📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
Everest Medicines Ltd
Everest Medicines's GHG Emissions Data Preview
In 2024, Everest Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Everest Medicines has also provided a category-level breakdown for 3 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  c | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data. | 0000000 |
a
b
c
a
a
b
cVerified Sources Behind Everest Medicines’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Everest Medicines’s data sources below and access millions more through our Disclosure Search.
Insights into Everest Medicines's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions ofEverest Medicines amounted to4,230.34metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Everest Medicinesdecreased by 24.71%, showing that the company has made progress in taking action to reduce the climate impact of its operations.ab
Everest Medicines's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Everest Medicines's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Everest Medicines were 0.5 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Compared to the previous year(2023), Everest Medicines's Scope 1 emissions increased by 19.05%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.ab
What are Everest Medicines's Scope 2 emissions?
In 2024, Everest Medicines reported Scope 2 greenhouse gas (GHG) emissions of 4,229.84 tCOâ‚‚e without specifying the calculation method.a
Has Everest Medicines reduced its Scope 2 emissions over time?
Since 2022, Everest Medicines's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method)have increased by 614.09%, reflecting a rising long-term trend in Scope 2 emissions over time.ac
Compared to the previous year(2023), Everest Medicines's Scope 2 emissions(Unspecified Calculation Method) fell by 24.71% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.ab
What methodology does Everest Medicines use for Scope 2 reporting?
In 2024, Everest Medicines reported its Scope 2 emissions using an unspecified methodology.a
Everest Medicines's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Everest Medicines's Value Chain Emissions
In 2024, Everest Medicines reported 699.3 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Everest Medicines includes a breakdown across 3of the 15 Scope 3 categories defined by the GHG Protocol,up from 2 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
Everest Medicines's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Everest Medicines's Scope 3 emissions?
In 2024, Everest Medicines reported total Scope 3 emissions of 699.3 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Approximately 100%of these emissions originated from upstream activities such as purchased goods and capital goods, while 0%came from downstream activities like product use, distribution, and end-of-life treatment.a
Has Everest Medicines reduced its Scope 3 emissions over time?
Since 2022, Everest Medicines's Scope 3 emissionshave increased by 1,521.75%, reflecting a rising long-term trend in Scope 3 emissions over time.ac
Compared to the previous year (2023), Everest Medicines's Scope 3 emissions increased by 41.64%, suggesting that the company faced challenges in reducing emissions across its value chain.ab
What categories of Scope 3 emissions does Everest Medicines disclose?
In 2024, Everest Medicines reported emissions for 3 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Everest Medicines's Scope 3 emissions?
In 2024, the largest contributors to Everest Medicines's Scope 3 emissions were:a
- Business Travel (Cat. 6): 630.5 tCOâ‚‚e(90.16%)
- Fuel- and Energy-Related Services (Cat. 3): 64.85 tCOâ‚‚e(9.27%)
- Waste Generated in Operations (Cat. 5): 3.95 tCOâ‚‚e(0.56%)
Everest Medicines's Scope 3 Emissions by Categories
Insights into Everest Medicines’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Everest Medicines reported Scope 1 greenhouse gas (GHG) emissions of 0.5 tCOâ‚‚e and total revenues of USD 106 millions. This translates into an emissions intensity of 0 tCOâ‚‚e per millions USD.a
Everest Medicines's Scope 1 Emissions Intensity Compared to Peers
How does Everest Medicines's GHG emissions intensity compare to its peers?
In 2024, Everest Medicines reported a Scope 1 emissions intensity of 0 tCOâ‚‚e per millions USD. Compared to the peer group median of 9.75, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
Where does Everest Medicines rank on GHG emissions intensity within its industry?
In 2024, Everest Medicines ranked 1 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
This places Everest Medicines among the top performers, with one of the lowest emissions intensities relative to peers.a
Insights into Everest Medicines's Total Carbon Footprint
In 2024, Everest Medicines reported a total carbon footprint of 4,929.64 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 19.35% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.ab
The largest contributor to Everest Medicines's total carbon footprint was Scope 2 emissions, accounting for 85.8% of the company's total carbon footprint, followed by Scope 3 emissions at 14.19%.a